Scholarlink

<p>This study evaluated the antibacterial potential of a novel metabolite, a lansoprazole-like structure (LPZS), derived from the marine actinomycete <i>Streptomyces huiliensis</i> (PQ285591) against <i>Staphylococcus aureus</i> (MSSA). Out of 30 marine isolates from the Mediterranean Sea, <i>S. huiliensis</i> exhibited the most potent bioactivity. The purified metabolite, identified via NMR, TLC, HPLC, and GC–MS, demonstrated a significant minimum inhibitory concentration (MIC) of 0.5&#xa0;μg/mL against <i>S. aureus</i> in vitro. The in vivo efficacy and safety were assessed using 120 African catfish (<i>Clarias gariepinus</i>) challenged with <i>S. aureus</i> (1.6 × 10⁶ CFU/mL). Treatment with LPZS (100&#xa0;μg/mL) significantly (<i>p</i> &lt; 0.05) mitigated infection-induced mortality and clinical symptoms. Furthermore, LPZS administration improved hepatorenal biomarkers, enhanced nonspecific immune responses (lysozyme and nitric oxide), and bolstered antioxidant capacity. Histopathological examination confirmed that LPZS effectively reversed tissue damage in the liver, kidney, and spleen. These findings suggest that LPZS is a safe and potent antibacterial agent, offering a promising therapeutic alternative for managing staphylococcal infections in aquaculture.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A lansoprazole-like structure derived from Streptomyces metabolites: evaluation of its protective effects on hepatorenal function, antioxidant activity, and immune parameters in African catfish challenged with Staphylococcus aureus

  • 期刊论文

  • 发表日期：

    2026年5月19日

查看全文
  • Rewan Abdelaziz,
  • Saeedah M. Almutairi,
  • Mohamed R. AbdelGawwad,
  • Kasim Sakran Abass,
  • Sheeren Abdelaziz,
  • Azza SalahEldin El-Demerdash,
  • Riyadh Alotaibi,
  • Mohamed Taha Yassin

摘要

This study evaluated the antibacterial potential of a novel metabolite, a lansoprazole-like structure (LPZS), derived from the marine actinomycete Streptomyces huiliensis (PQ285591) against Staphylococcus aureus (MSSA). Out of 30 marine isolates from the Mediterranean Sea, S. huiliensis exhibited the most potent bioactivity. The purified metabolite, identified via NMR, TLC, HPLC, and GC–MS, demonstrated a significant minimum inhibitory concentration (MIC) of 0.5 μg/mL against S. aureus in vitro. The in vivo efficacy and safety were assessed using 120 African catfish (Clarias gariepinus) challenged with S. aureus (1.6 × 10⁶ CFU/mL). Treatment with LPZS (100 μg/mL) significantly (p < 0.05) mitigated infection-induced mortality and clinical symptoms. Furthermore, LPZS administration improved hepatorenal biomarkers, enhanced nonspecific immune responses (lysozyme and nitric oxide), and bolstered antioxidant capacity. Histopathological examination confirmed that LPZS effectively reversed tissue damage in the liver, kidney, and spleen. These findings suggest that LPZS is a safe and potent antibacterial agent, offering a promising therapeutic alternative for managing staphylococcal infections in aquaculture.